Natriuretic peptide: diagnostic, profnostic, and clinical relevance in patients with type 2 diabetes mellitus, arterial hypertension and obesity

Abstract

Natriuretic peptides are one of the main biomarkers of chronic heart failure (CHF). The level of NT-proBNP makes it possible to evaluate the negative prognosis in patients with CHF, as well as to monitor the sensitivity of patients with left ventricular dysfunction to the appointment of treatment. The purpose of the study: to study the NT-proBNP biomarker in comorbid patients with hypertension, obesity, type 2 diabetes and determine the relationship with a number of hormonal and biochemical indicators. Materials and methods: all patients were divided into 4 groups depending on the presence of comorbid pathology in them: patients with hypertension — 1 group — 22 people; patients with hypertension combined with obesity — group 2 — 30 people; Hypertension in combination with type 2 diabetes — group 3 — 31 people; patients with hypertension, type 2 diabetes and obesity — group 4 — 28 people. Determination of the content of N-terminal brain natriuretic peptide (NT-proBNP) in the blood serum of patients was carried out by the immu-noenzymatic method on the analyzer «Labline-90» (Austria) using a commercial test system manufactured by the company «Elabscience» (ELISA, China) according to the instructions, which was part of the set. Conclusions. It was established that in patients with hypertension, hypertension in combination with obesity, hypertension in combination with type 2 diabetes, as well as hypertension in combination with type 2 diabetes and obesity, there is a significant increase in NT-proBNP compared to the indicator of the control group (p < 0.05). It has been proven that NT-proBNP has a direct correlation with creatinine (p = 0.045), urea (p = 0.038), triglyceride level (p = 0.027) and cholesterol (p = 0.031); direct correlation with the level of HbA1c (r = 0.202; p = 0.0038). The level of NT-proBNP has a significant predictive value for the risk of developing car-diovascular complications in patients with hypertension.